TNFRSF10B and neoplasm: At present, the research on the mechanism of drug resistance (Kim et al., 2018; Gupta et al., 2013) of DR5 agonists has attracted much attention, and the future research on DR5 agonists as tumor targeted therapy will focus on the novel DR5 agonists design (Schneider et al., 2010; Li et al., 2024), combination therapy (Zheng et al., 2023; Casagrande Raffi et al., 2024) and new delivery system development, etc., aiming to improve targeted efficacy and safety.